Physician profile
Jonathan Davis
NPI 1801079330
$6,904.68
in general payments reported to CMS, 2019-2025
33 companies · $3,331 in 2025
The $3,331 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $125 · 2021: $595 · 2022: $860 · 2023: $777 · 2024: $580 · 2025: $3,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815 · Travel and Lodging: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.87 |
| Travel and Lodging | $1,873.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,324.90 | 2021-2025 | Xience Skypoint, Dragonfly Opstar, Diamondback Coronary |
| Medtronic, INC. | $735.94 | 2022-2025 | Symplicity G3, Ffrangio, Cobalt Dr Mri Surescan |
| Abiomed | $735.27 | 2019-2025 | Impella |
| Pfizer INC. | $473.84 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $375.65 | 2020-2025 | Lifevest |
| Shockwave Medical, INC | $339.99 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $329.40 | 2019-2025 | Wolverine Coronary Cutting Balloon, Accolade Sr, Jetstream Sc |
| Penumbra, INC. | $239.43 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $232.82 | 2021-2022 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Edwards Lifesciences Corporation | $120.70 | 2019 | |
| Itamar Medical INC | $113.17 | 2022-2025 | Watchpatone |
| E.R. Squibb & Sons, L.L.C. | $86.71 | 2019-2023 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $68.36 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $60.80 | 2023-2024 | Verquvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $54.88 | 2019-2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.18 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $49.13 | 2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $46.12 | 2019-2023 | |
| Recor Medical INC | $45.15 | 2024 | Paradise Renal Denervation System |
| Cvrx, INC. | $37.56 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $33.24 | 2023-2024 | |
| Astellas Pharma US INC | $30.08 | 2019 | |
| Philips North America LLC | $29.60 | 2025 | Mcot, Ecc Solutions |
| Kiniksa Pharmaceuticals, LTD. | $29.10 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $24.18 | 2024 | Andexxa |
| Chiesi USA, INC. | $18.65 | 2022 | |
| United Therapeutics Corporation | $18.14 | 2023 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $16.04 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.85 | 2025 | Amvuttra |
| Amgen INC. | $14.80 | 2019 | |
| Medtronic Vascular, INC. | $13.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.